论文部分内容阅读
目的：研究猕猴单次注射ＣＨＯ细胞表达的重组人血小板生成素（ｒｈＴｐｏ）后药动学及血小板计数变化．方法：酶联免疫吸附测定法（ＥＬＩＳＡ）检测血清中ｒｈＴｐｏ含量．血细胞计数仪进行血小板计数．结果：ｒｈＴｐｏ末端相半衰期（Ｔ１２β）１２－１８ｈ．各ｓｃ组间ＡＵＣ依赖于剂量，而Ｃｌｓ相近．生物利用度０５０±０１８．ｒｈＴｐｏ引起猕猴与剂量相关的血小板增加（平均增加率５５９％－１０７４％，Ｐ＜００５）．增加峰值及持续天数与剂量有关．结论：ｒｈＴｐｏ在猕猴体内表现为线性药动学．ｒｈＴｐｏＴ１２β长与其分子量大，高度糖基化有关．血小板增加程度（血小板净增率×持续时间）与ｒｈＴｐｏ全身暴露强度（血药浓度×时间）呈正相关．
Objective: To study the changes of pharmacokinetics and platelet count of recombinant human thrombopoietin (rhTpo) expressed in CHO cells of a single injection of macaque. Methods: The content of rhTpo in serum was detected by enzyme - linked immunosorbent assay (ELISA). Blood cell count for platelet count. Results: The half-life of rhTpo terminal phase (T12β) 12-18h. The AUCs for each sc group were dose-dependent and Cls were similar. Bioavailability 050 ± 018. RhTpo caused dose-related thrombocytosis in rhesus monkeys (mean rate of increase 559% -1074%, P <005). Increase the peak and the number of days and dose-related. Conclusion: rhTpo appears as a linear pharmacokinetic in rhesus monkeys. The long rhTpoT12β is associated with its high molecular weight and high glycosylation. The extent of thrombocytopenia (net increase in platelets × duration) was positively correlated with the systemic exposure to rhTpo (plasma concentration × time).